Australian researchers have developed a new targeted immunotherapy approach for myelofibrosis, a rare blood cancer that disrupts healthy blood cell production. Published in the journal Blood, the study focuses on identifying and targeting abnormal cells driving the disease, aiming for more effective treatments than current symptom management. This precision immunology approach utilizes the immune system to recognize and eliminate disease-causing cells while sparing healthy ones, potentially leading to potent, long-lasting, and precise therapies.